拉米夫定、复方甘草酸苷联合还原型谷胱甘肽治疗慢性乙肝肝硬化的效果观察

Abstract
Figure/Table
References (15)
Related Citation (11)

Download: PDF (0 KB) HTML (24 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the therapeutic value of Lamivudine and Compound Glycyrrhizin combined with Reduced Glutathione in joint application in patients with chronic hepatitis B associated liver cirrhosis.Methods A total of 56 patients with chronic hepatitis B associated liver cirrhosis treated in our hospital from October 2016 to December 2017 were selected as sujects.By computer randomization method,they were evenly divided into control group and experimental group,28 cases in each group.In the control group,Lamivudine was used,while in the experimental group,Compound Glycyrrhizin and Reduced Glutathione were added.The total bilirubin(TBil),aspartate aminotransferase(AST),alanine aminotransferase(ALT)levels and therapeutic effects were compared between the two groups.Results The levels of TBil,AST and ALT in the two groups after treatment were all lower than those before treatment,and the above mentioned indexes in the experimental group after treatment were significantly lower than those in the control group,the differences were statistically significant(P＜0.05).The total effectiveness rate in the experimental group was 92.86%,which was significantly higher than that of the control group accounting for 64.29%,the difference was statistically significant(P＜0.05).Conclusion Joint application of Lamivudine,Compound Glycyrrhizin and Reduced Glutathione for patients with chronic hepatitis B cirrhosis can effectively inhibit the replication of the virus and has positive clinical significance for prognosis improvement.

Key words： Lamivudine Reduced Glutathione Compound Glycyrrhizin Hepatitis B cirrhosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Shao-wen

Cite this article:

CHEN Shao-wen. Effect observation of Lamivudine and Compound Glycyrrhizin combined with Reduced Glutathione on chronic hepatitis B associated liver cirrhosis[J]. 中国当代医药, 2018, 25(14): 142-144.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I14/142

[1]	王烈，胡义忠，徐秀亮，等.血清 sP-selectin、sICAM-1 和免疫球蛋白检测对乙肝肝硬化预后评估的意义[J].中国免疫学杂志，2017，33（11）：1699-1705.
[2]	陈敏，朱俊，张敬，等.复方甘草酸苷联合还原型谷胱甘肽治疗酒精性肝硬化的疗效观察[J].胃肠病学和肝病学杂志，2014，23（5）：506-508.
[3]	陈淋丽.慢性乙型肝炎护肝治疗患者肝硬化的临床危险因素研究[J].当代医学，2016，22（3）：32-33.
[4]	王郁杰，秦宝山，王志凌，等.乙型肝炎肝硬化患者拉米夫定联合阿德福韦酯治疗后胆囊收缩功能的变化[J].重庆医学，2013，42（18）：2137-2138.
[5]	赵立新，卢天虎，庄海，等.回顾性分析拉米夫定联合阿德福韦酯治疗HBeAg阳性失代偿期乙肝肝硬化患者的临床疗效[J].中国生化药物杂志，2015，40（4）：91-93.
[6]	汪平莉，朱春丽.拉米夫定治疗失代偿期乙肝肝硬化的疗效及不良反应[J].中国老年学杂志，2014，34（5）：1378-1379.
[7]	焦一鸣，王放.三十五年来中医药在防治慢性病毒性肝炎中的地位变化[C].//世界中联第六届肝病国际学术大会论文集，2015：162-165.
[8]	杨崎恩，蒋亦明，孙彤，等.拉米夫定联合阿德福韦酯治疗老年失代偿期乙肝后肝硬化的临床疗效[J].中国老年学杂志，2015，35（6）：1518-1520.
[9]	邱冰峰，徐骐，徐汤舟，等.拉米夫定对乙型肝炎肝硬化患者肝纤维化状态与血小板参数的影响研究[J].中华医院感染学杂志，2016，26（8）：1700-1702.
[10]	刘爱兵，李宗军，何新明，等.阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化失代偿期的临床疗效[J].重庆医学，2015，44（34）：4812-4814.
[11]	张颖慧，李良平，张笛，等.拉米夫定与阿德福韦酯初始联合与单药优化治疗代偿期乙型肝炎肝硬化的疗效比较[J].重庆医学，2017，46（29）：4077-4080.
[12]	赵铭，丁顺斌，江小云，等.复方甘草酸苷联合还原型谷胱甘肽治疗酒精性肝硬化43例临床疗效分析[J].标记免疫分析与临床，2016，23（1）：38-41.
[13]	王景景，郭倩，田妍，等.还原型谷胱甘肽辅助治疗对肝硬化上消化道出血患者血管活性分子、氧化应激反应的影响[J].海南医学院学报，2017，23（19）：2620-2622，2626.
[14]	黄大群.应用还原型谷胱甘肽联合复方甘草酸苷治疗酒精性肝硬化的效果分析[J].当代医药论丛，2015，13（4）：146-147.
[15]	刘生水.还原型谷胱甘肽抗氧化联合常规抗病毒药物对乙肝肝硬化患者肝纤维化进程的影响[J].海南医学院学报，2017，23（16）：2188-2191.